PubRank

Mack Roach

Author PubWeight™ 148.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010 5.98
2 Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005 4.51
3 An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007 3.87
4 Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2011 3.10
5 Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012 2.86
6 Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol 2013 2.59
7 Prostate cancer, version 2.2014. J Natl Compr Canc Netw 2014 2.40
8 Low-dose megavoltage cone-beam CT for radiation therapy. Int J Radiat Oncol Biol Phys 2005 2.33
9 Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2006 2.33
10 High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012 2.06
11 Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004 2.04
12 Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 2002 1.85
13 Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012 1.84
14 Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys 2011 1.82
15 Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2006 1.81
16 Megavoltage cone-beam CT: system description and clinical applications. Med Dosim 2006 1.74
17 Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys 2007 1.69
18 Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: a step forward. Int J Radiat Oncol Biol Phys 2013 1.55
19 Clinical decisions. Management of prostate cancer. N Engl J Med 2008 1.49
20 Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2002 1.49
21 Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 2008 1.46
22 Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 2005 1.42
23 Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin 2005 1.41
24 Prostate movement during simulation resulting from retrograde urethrogram compared with "natural" prostate movement. Int J Radiat Oncol Biol Phys 2004 1.39
25 Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004 1.36
26 Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 2010 1.35
27 Prostate cancer, version 1.2014. J Natl Compr Canc Netw 2013 1.32
28 Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 2010 1.29
29 Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res 2004 1.28
30 Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys 2007 1.27
31 Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys 2013 1.25
32 The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets. Int J Radiat Oncol Biol Phys 2002 1.15
33 Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004 1.15
34 Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2008 1.14
35 Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2008 1.11
36 Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys 2004 1.11
37 Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys 2008 1.11
38 Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004 1.10
39 Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. Am J Clin Oncol 2009 1.09
40 Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2006 1.08
41 Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys 2006 1.08
42 Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys 2010 1.07
43 Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys 2002 1.05
44 Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008 1.05
45 Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 2013 1.02
46 Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology 2010 1.01
47 A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2012 1.01
48 (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys 2003 1.01
49 Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys 2012 1.00
50 Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010 1.00
51 Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 2009 1.00
52 Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience. Radiology 2008 0.99
53 Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 2012 0.99
54 Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97-14. J Palliat Med 2008 0.98
55 Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys 2004 0.95
56 Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys 2003 0.94
57 Positional stability of electromagnetic transponders used for prostate localization and continuous, real-time tracking. Int J Radiat Oncol Biol Phys 2007 0.94
58 Functional interference clusters in cancer patients with bone metastases: a secondary analysis of RTOG 9714. Int J Radiat Oncol Biol Phys 2009 0.93
59 Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol 2007 0.93
60 Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007 0.92
61 Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol 2014 0.92
62 ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate. Int J Radiat Oncol Biol Phys 2009 0.92
63 Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys 2011 0.91
64 Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys 2012 0.91
65 Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 2004 0.91
66 Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy 2007 0.90
67 Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy. Brachytherapy 2011 0.90
68 Permanent prostate seed brachytherapy: a current perspective on the evolution of the technique and its application. Nat Clin Pract Urol 2007 0.90
69 High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes. Int J Radiat Oncol Biol Phys 2010 0.90
70 Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Radiat Oncol 2013 0.90
71 Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable. Int J Radiat Oncol Biol Phys 2009 0.90
72 Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife. J Appl Clin Med Phys 2013 0.90
73 Technique for implantation of fiducial markers in the prostate. Urology 2008 0.90
74 Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys 2005 0.86
75 Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2008 0.86
76 Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol 2002 0.86
77 Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer 2013 0.84
78 Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer. Brachytherapy 2005 0.84
79 Successful radiation treatment of anaplastic thyroid carcinoma metastatic to the right cardiac atrium and ventricle in a pacemaker-dependent patient. Radiat Oncol 2011 0.84
80 Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol 2005 0.83
81 Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev 2012 0.83
82 Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am J Clin Oncol 2006 0.83
83 Radiation medicine innovations for the new millenium. J Natl Med Assoc 2003 0.83
84 Is it time to change the standard of care from CT to MRI for defining the apex of the prostate to accomplish potency-sparing radiotherapy? Int J Radiat Oncol Biol Phys 2005 0.83
85 Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era. Cancer 2005 0.82
86 Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. Int J Radiat Oncol Biol Phys 2010 0.82
87 An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodes. Med Phys 2007 0.82
88 Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413. Urology 2008 0.81
89 Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk? J Clin Oncol 2007 0.81
90 Computer-assisted, atlas-based segmentation for target volume delineation in whole pelvic IMRT for prostate cancer. Technol Cancer Res Treat 2012 0.80
91 Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 2002 0.79
92 Radium-223 vs EBRT for multiple painful bone metastases: is less more? Oncology (Williston Park) 2014 0.78
93 Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys 2006 0.78
94 Comparison of three strategies in management of independent movement of the prostate and pelvic lymph nodes. Med Phys 2010 0.78
95 New techniques and management options for localized prostate cancer. Rev Urol 2006 0.78
96 A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2003 0.78
97 Integrating hormonal therapy with external-beam radiation and brachytherapy for prostate cancer. Oncology (Williston Park) 2005 0.77
98 Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer. Neoplasia 2007 0.77
99 Indications and practice with androgen deprivation therapy. Urology 2011 0.77
100 Traditional approaches to androgen deprivation therapy. Urology 2011 0.77
101 Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials. J Clin Oncol 2008 0.77
102 State-of-the-art radiotherapy in the management of clinically localized prostate carcinoma. Future Oncol 2007 0.77
103 Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008 0.76
104 High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. Brachytherapy 2009 0.76
105 "Short- and long-term mortality with localized prostate cancer": errors and omissions? Arch Intern Med 2008 0.76
106 Are lateral electronic portal images adequate for accurate on-line daily targeting of the prostate? Results of a prospective study. Med Dosim 2008 0.76
107 The evolving role of pelvic radiation therapy. Semin Radiat Oncol 2003 0.76
108 Editorial comment on: high provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. Eur Urol 2007 0.75
109 Neoadjuvant hormonal therapy in men being treated with radiotherapy for localized prostate cancer. Rev Urol 2004 0.75
110 Radium-223: down to the bone, and less is more. Oncology (Williston Park) 2012 0.75
111 Endorectal MRI after radiation therapy: questioning the sextant analysis. J Magn Reson Imaging 2011 0.75
112 Predicting the risk of pelvic node involvement in men with prostate cancer in the contemporary era: change you can believe?: in regard to Yu, et al. (Int J Radiat Oncol Biol Phys in press). Int J Radiat Oncol Biol Phys 2011 0.75
113 "Supplemental beam" and prostate brachytherapy: a simple answer to a complicated question? Int J Radiat Oncol Biol Phys 2003 0.75
114 Cautious optimism for extreme dose escalation in prostate cancer. Eur Urol 2013 0.75
115 Who, when, where, and how: salvage prostate cancer with radiotherapy. Oncology (Williston Park) 2010 0.75
116 Long-term potency preservation following brachytherapy for prostate cancer. BJU Int 2012 0.75
117 Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the Stephenson nomogram. Int J Radiat Oncol Biol Phys 2012 0.75
118 Commentary on increased risk of biochemical and local failure in patients with a distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2005 0.75
119 Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy. Radiother Oncol 2013 0.75
120 Radical prostatectomy or external beam radiotherapy: one step forward or two steps back? Cancer 2002 0.75
121 Prostate cancer: worse sexual function after cryoablation--a case for EBRT? Nat Rev Urol 2010 0.75
122 Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer 2014 0.75
123 Editorial comment. Urology 2011 0.75
124 Editorial comment. J Urol 2009 0.75
125 Do not count out external-beam radiation therapy for high-risk prostate cancer. J Clin Oncol 2010 0.75
126 Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes. PLoS One 2016 0.75
127 Editorial comment. Urology 2011 0.75
128 Promoting wellness for patients on androgen deprivation therapy: why using numerous drugs for drug side effects should not be first-line treatment. Urol Clin North Am 2011 0.75
129 Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era: change you can believe in, or back to the future? (In regard to Nguyen PL, et al. (Int J Radiat Oncol Biol Phys 2009). Int J Radiat Oncol Biol Phys 2009 0.75
130 Predicting pathologic stage, nomograms, and clinical judgment: don't miss the forest for the trees! Int J Radiat Oncol Biol Phys 2009 0.75
131 Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: "love the one you're with" and "do the right thing". Int J Radiat Oncol Biol Phys 2003 0.75
132 Benefits and pitfalls of prostate cancer screening: "no proof of benefit" does not equal "proof of no benefit". Oncology (Williston Park) 2011 0.75
133 Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy. Phys Med Biol 2011 0.75
134 Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery. Am J Clin Oncol 2016 0.75
135 Radiotherapy in the management of common genitourinary malignancies. Hematol Oncol Clin North Am 2006 0.75
136 Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. Semin Radiat Oncol 2002 0.75
137 Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapy. Int J Radiat Oncol Biol Phys 2008 0.75
138 Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol 2003 0.75